The Product

pTeroSol® is the water-soluble fraction prepared from the heartwood of Indian Kino (Pterocarpus marsupium) and standardized for a minimum of 5% C-glycosides (as Pterocarposide and Sabioside).

SOURCE AND TRADITIONAL USE

Pterocarpus marsupium, recognized in Ayurvedic practice for its support of metabolic health, has been traditionally utilized through the preparation of water infused with its wood. This traditional method highlights the historical use of natural elements in promoting well-being and managing health concerns, reflecting a holistic approach to dietary and lifestyle practices for supporting balanced metabolic functions.

Exploring natural strategies for glucose regulation such as via sodium-glucose cotransport (SGLT2) mechanism, research highlights the potential of specific compounds to influence glucose reabsorption processes, offering a nuanced approach to supporting metabolic health through dietary and lifestyle adjustments.

CHEMISTRY

Pterocarpus marsupium contains several naturally occurring C-glycosides, which may be responsible for maintaining healthy blood sugar levels. The two water-soluble C-glycoside compounds prepared from the heartwood of P. marsupium are Pterocarposide and Sabioside (new compound isolated by Sami-Sabinsa Group).

pterosol

Pterocarposide (I) and Sabioside (II) from P. marsupium heartwood

PROPERTIES OF C-GLYCOSIDES

  • Aromatic and heteroaromatic, in which the glucose moiety binds aglycone directly through a carbon-carbon bond
  • It enhances the chemical stability of the glycosidic bond
  • They are rapidly absorbed in the gastrointestinal tract without modification of the prodrug form
  • Found to be an effective sodium-glucose co-transporter 2 (SGLT2) inhibitors

MECHANISM OF ACTION

Exploring natural strategies for glucose regulation such as via sodium-glucose cotransport (SGLT2) mechanism, research highlights the potential of specific compounds to influence glucose reabsorption processes, offering a nuanced approach to supporting metabolic health through dietary and lifestyle adjustments.

pterosol

CLINICAL EVIDENCE

Study 1

A multi-center, 12-week, flexible-dose, open-trial involving newly-diagnosed type 2 (NIDDM) subjects was carried out to assess the efficacy of Pterocarpus extract. Subjects were supplemented with increasing doses of Pterocarpus extract (i.e 2 g, 3 g, and 4 g at a gap of 4 weeks each). At the end of 12 weeks, 69% of subjects showed significant control of blood glucose (both fasting and postprandial) levels. Additionally, mean HbA1c was found to be decreased significantly at the end of the trial. There were no side-effects reported during the study period. Thus, Pterocarpus extract may be helpful in the treatment of newly-diagnosed or untreated mild NIDDM subjects (Indian J Med. Res,1998).

pterosol

Fasting and postprandial blood glucose levels measured at baseline and at 12 weeks


Study 2

In another 36-week, randomized, double-blind, multi-centre, flexible-dose trial, blood lowering effect of dried aqueous extract of the heartwood of P. marsupium was compared with that of Tolbutamide, in newly-diagnosed or untreated type 2 diabetic subjects. Subjects were randomly divided into Pterocarpus extract group (n=172) and Tolbutamide group (n=177) and were treated with increasing dosage (i.e Pterocarpus extract: 2 g, 3 g and 4 g/day and Tolbutamide: 0.75 g, 1 g, and 1.5 g/day) at a gap of 4 weeks each. Results demonstrated that supplementation with Pterocarpus extract was able to lower blood glucose levels in 86% subjects, which was comparable to Tolbutamide efficacy (i.e. 94%). Hence, it was concluded that Pterocarpus extract could be an effective blood glucose lowering agent in type 2 diabetes without any significant side effects (Diabetologia Croatica, 2005).

Blood Glucose Levels (mmol/L)
Parameter Drug Group At baseline At 36 weeks
Fasting Pterocarpus extract (n=172) 9.4 7.0
Tolbutamide (n=177) 9.4 6.7
Postprandial Pterocarpus extract (n=172) 13.9 9.6
Tolbutamide (n=177) 13.8 9.4

FORMULATIONS

pTeroSol® can be used as a dietary supplement in the form of tablets, capsules, and powder premixes.

PATENTS

IN192163#
process for isolation of novel compound 2,6-dihydroxy-2(p-hydroxybenzyl)-3(2H)-benzofuranone-7- C-ß-D-glucopyranoside from Pterocarpus marsupium.


IN194292#
A process for extraction of antidiabetic formulation mainly containing flavonoid glycosides.

PUBLICATIONS

  1. ICMR study group (2005). Efficacy of vijaysar (Pterocarpus marsupium) in the treatment of newly diagnosed patients with type 2 diabetes mellitus: A flexible dose double blind multi-centre randomised controlled trial. Diabetologia Croatica. 34(1): 13-20
  2. ICMR study group (1998). Flexible dose open trial of Vijaysar in case of newly diagnosed noninsulin-dependent diabetes mellitus. Ind J Med Res. 1998, 108: 24-29

#Sami-Sabinsa acquired these two patents pertaining to Pterocarpus marsupium by entering into tripartite agreement with Indian Institute of Integrative Medicine (IIIM) and the Council of Medical Research (ICMR).

Disclaimers

Sabinsa does not have a legal binding obligation for the information mentioned in this document, or further answers/information provided thereof. The data and information contained herein are believed to be accurate presented in good faith only for your guidance. Sabinsa recommends that further tests be conducted accordingly to the suitability of the product for specific application/use. Our customers are open to perform a full inspection of the products upon delivery or any other obligation. Sabinsa does not provide any warranties of any kind regarding the products described or designs, data or information set forth, or the use of the products, designs, data or information without infringing the intellectual property rights of others. Under no circumstances the information, data or designs provided shall be considered a part of our terms and conditions of sale.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure,or prevent any disease. Health claims are not evaluated and approved by EFSA as per EC regulation 1924/2006. FAQ_02.